Hologic Inc

Hologic — Cytyc — Merger or Acquisition (June 2007)

31 slides from Hologic's merger presentation, Jun 20, 2007

  1. Slide 1: NASDAQ 19th Investor Program

    NASDAQ 19 th Investor Program Jack W. Cumming Chairman & CEO June 2007 Filed by Hologic, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Cytyc Corporation Commission File No.: 000-27558

  2. Slide 2: Disclaimer Regarding Forward-Looking Statements

    Disclaimer Regarding Forward-Looking Statements Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Hologic’s

  3. Slide 3: Disclaimer Regarding Forward-Looking Statements (continued)

    Disclaimer Regarding Forward-Looking Statements (continued) growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies, including third-party reimbursement; realization of potential future savings from new productivity init

  4. Slide 4: Important Information for Investors and Stockholders

    Important Information for Investors and Stockholders Hologic and Cytyc will file a joint proxy statement/prospectus with the SEC in connection with the proposed merger. HOLOGIC AND CYTYC URGE INVESTORS AND STOCKHOLDERS TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OT

  5. Slide 5: Participants in the Solicitation

    Participants in the Solicitation Hologic, and certain of its directors and executive officers, may be deemed participants in the solicitation of proxies from the stockholders of Hologic in connection with the merger. The names of Hologic’s directors and executive officers and a description of their

  6. Slide 6: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures "adjusted EPS" and “EBITDA”. Adjusted EPS excludes the write-off and amortization of acquisition-related intang

  7. Slide 7: A History of Innovation

    A History of Innovation Delphi HOLOGIC Goes Public Acquisition of Trex Medical Including LORAD Selenia Launched in U.S. Introduced 3D DEXA Acquisition of R2, Suros and AEG Fan-Beam Technology Founding of HOLOGIC Announced Agreement with Cytyc Introduced Tomosynthesis at RSNA Launched Discovery Acqui

  8. Slide 8: Financial Overview

    Financial Overview Record Q2 FY07 revenues of $180 million Record Q2 FY07 pre-tax income of $33.9 million Backlog of $216 million as of quarter-end 3/31/07 Q2 FY07 Performance (March 31st) up 79% over Q2 FY06 up 94% over Q2 FY06 up 41% or $63 million over 3/25/06 Strong Growth

  9. Slide 9: Mammography / Breast Health

    $129 $189 $336 Up 99% Over 1 st Half FY06 Mammography / Breast Health Recognized technology leader worldwide Market share leader in the U.S. > 55% share in analog/digital 78% of total revenues Unsurpassed image quality – High transmission cellular grid - patented Largest installed base – 13,000 syst

  10. Slide 10: MQSA U.S. Scorecard

    MQSA U.S. Scorecard* (Mammography Quality Standards Act of 1992) Total Certified Facilities 8,812 Total Accredited Units 13,446 Certified Facilities with FFDM Units 1,884 21.4% Accredited FFDM Units 2,773 20.6% Total U.S. Annual = 34.8 Million Mammography Procedures Hologic U.S. Installed Base appro

  11. Slide 11: Product Pipeline

    Product Pipeline Interventional products to address extraction of benign fibroid adenomas – 350-500k procedures per year Percutaneous removal of confirmed breast cancer – 75-100k procedures per year Radiation oncology for treatment of breast cancer Digital Tomosynthesis

  12. Slide 12: SUOT[IA WH S.$ JeHUa}Og oNUAADY

    SUOT[IA WH S.$ JeHUa}Og oNUAADY { HOLOGIC

  13. Slide 13: Tomosynthesis: 3-D Visualization of Breast Tissue

    Normal Mammogram Tomosynthesis: 3-D Visualization of Breast Tissue The Next Frontier for Digital Mammography Multiple views reconstructed into 3D image Helps solve tissue overlap problems Lower recall rates - Improved detection Tomosynthesis Slices * Works-in-progress

  14. Slide 14: Slide 14

  15. Slide 15: Vacuum Assist Breast Biopsy Systems

    Vacuum Assist Breast Biopsy Systems Leading technology for VABB Leverages U.S. sales and distribution channels FY06 sales of approximately $38 million – High gross margin product exceeding 65% – Over 70% of revenues derived from recurring disposable sales – Expected growth rate of over 50% in each o

  16. Slide 16: Celero

    Celero ™ - The First Vacuum-Assisted, Spring- Loaded Core Biopsy Device for Breast Ultrasound Celero breast biopsy device with CeleroMark™ biopsy marker system and introducer Celero Advantages - Faster and less traumatic for the patient - Provides better access to hard-to-reach lesions - Better core

  17. Slide 17: Ideally Positioned to Capture the Biopsy Market

    Ultrasound Stereotactic MRI 500,000 (ATEC Market) 1.8 Million Breast Biopsy Procedures Annually in the U.S. 600,000 (Celero Market) 700,000 Suros ATEC ® and Celero Systems Ideally Positioned to Capture the Biopsy Market

  18. Slide 18: Creating a Global Leader in Women's Healthcare

    Creating a Global Leader in Women’s Healthcare Continuing a legacy of leading technology, innovation and rapid growth

  19. Slide 19: Company Strategy

    Top-line Growth Financial Discipline Leading Edge Technology Maintain Market Leadership Mission: Create the Global Leader in Women’s Healthcare Company Strategy Drive market growth through a combination of advanced technology and comprehensive sales channel coverage Continue 20%+ revenue and earning

  20. Slide 20: Hologic Remains the Technology Leader in an Expanding Market

    Hologic Remains the Technology Leader in an Expanding Market Best-in-Class Technology Leading innovator in women’s health technology – 1996: Liquid-based pap testing transforms cervical cancer testing – 2003: Digital mammography improves breast cancer screening outcomes Strong research and developme

  21. Slide 21: Comprehensive Women's Healthcare Platform

    MultiCare Stereotactic Biopsy #1 Discovery Osteoporosis Screening #1 Selenia Breast Cancer Screening #1 MammoSite Radiation Therapy #1 ThinPrep Pap Test Cervical Cancer Screening #1 Adiana Contraception NM FullTerm - Adeza Preterm Labor #1 Suros Biopsy Systems #2 Comprehensive Women’s Healthcare Pla

  22. Slide 22: {.HOLOGIC

    {.HOLOGIC Thal

  23. Slide 23: Slide 23

  24. Slide 24: Leveraging the OB/Gyn Channel

    Screening Test Diagnostic Test Treatment Specialist Therapeutic Improved Outcomes OB/Gyn Our Mission Leveraging the OB/GYN Channel Best Technology Selenia, ThinPrep, Adeza, Discovery Minimally Invasive Most Specific Suros, MultiCare, Selenia, Discovery Channel Access to Gatekeeper 230 OB/Gyn sales r

  25. Slide 25: Transaction Summary

    Advroyy, SB0p03UG) qeuonuaarazuy Summang { HOLOGIC’

  26. Slide 26: Diversified and Balanced Revenue Mix

    Combined Company (03/31/07 Revenue = $1.4 billion) Hologic (LQA 03/31/07 Revenue = $724 million) Cytyc (LTM 03/31/07 Revenue = $689 million) Breast Biopsy 9% Digital Mammography 68% Osteoporosis 11% Other 12% Breast Health 40% 60% Consumable / 40% Capital Equipment Pap 59% Diversified and Balanced R

  27. Slide 27: Transaction Overview

    Transaction Overview Permanent financing anticipated to be combination of pre-payable term loan and equity-linked securities Financing: Hologic, Inc. (NASDAQ: HOLX), continue Cytyc name Name of NewCo: Third Quarter of CY2007 Timing to Close: Shareholders of both companies, customary closing conditio

  28. Slide 28: Combined Financial Strength

    Combined Financial Strength 46% Gross Margin $161M EBITDA $724M Revenue LQA Hologic 75% Gross Margin $275M EBITDA $720M Revenue LQA Cytyc 60% Gross Margin $436M EBITDA $1.44B Revenue LQA Combined Company Estimated more than $0.10 accretive to adjusted EPS within the first full year after close - sig

  29. Slide 29: FY2008 Guidance and Long Term Outlook

    FY2008 Guidance and Long Term Outlook 2008 Guidance Revenue: In excess of $1.70B Adjusted EPS : $2.35-$2.40 / share Gross margin: 65% Long-Term Outlook Revenue Growth: 20% Adjusted EPS Growth: 20%+ Adjusted EPS excludes the write-off and amortization of acquisition-related intangible assets, and rel

  30. Slide 30: Creating a Global Leader in Women's Healthcare

    Creating a Global Leader in Women’s Healthcare Comprehensive Women’s Healthcare Product Portfolio – Complementary best-in-class technologies Expanded Commercial Capabilities – Expansive U.S. sales channel coverage – Enhanced presence in key international markets – Platform for entry into new markets

  31. Slide 31: Creating A Global Leader In Women's Healthcare

    Creating A Global Leader In Women’s Healthcare

Cytyc — Merger or Acquisition (June 2007) on 6ix